Ionis Pharmaceuticals (NASDAQ:IONS) Earns “Outperform” Rating from William Blair

Ionis Pharmaceuticals (NASDAQ:IONS)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued estimates for Ionis Pharmaceuticals’ FY2028 earnings at $2.07 EPS.

A number of other research firms have also commented on IONS. Royal Bank of Canada restated an “outperform” rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, September 26th. Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, November 7th. Guggenheim decreased their price target on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Finally, Piper Sandler decreased their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $60.65.

Ionis Pharmaceuticals Stock Up 0.1 %

Ionis Pharmaceuticals stock opened at $35.63 on Friday. The firm has a 50 day simple moving average of $37.38 and a 200 day simple moving average of $42.25. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals has a 1-year low of $33.33 and a 1-year high of $54.44. The firm has a market capitalization of $5.63 billion, a price-to-earnings ratio of -14.60 and a beta of 0.35.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 6,630 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the sale, the chief executive officer now owns 167,393 shares of the company’s stock, valued at $6,369,303.65. This trade represents a 3.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric Swayze sold 1,194 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48. Following the transaction, the executive vice president now owns 33,713 shares in the company, valued at $1,278,396.96. This represents a 3.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,877 shares of company stock valued at $299,578 in the last 90 days. Insiders own 2.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Ionis Pharmaceuticals by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock valued at $106,922,000 after acquiring an additional 183,814 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock worth $57,807,000 after purchasing an additional 114,914 shares during the period. ARK Investment Management LLC increased its stake in shares of Ionis Pharmaceuticals by 1.7% in the third quarter. ARK Investment Management LLC now owns 1,384,269 shares of the company’s stock worth $55,454,000 after purchasing an additional 23,244 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of Ionis Pharmaceuticals by 3.5% during the 3rd quarter. Two Sigma Advisers LP now owns 1,332,411 shares of the company’s stock valued at $53,376,000 after purchasing an additional 45,300 shares during the period. Finally, TD Asset Management Inc lifted its stake in shares of Ionis Pharmaceuticals by 6.1% during the 2nd quarter. TD Asset Management Inc now owns 952,762 shares of the company’s stock valued at $45,409,000 after buying an additional 54,400 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.